Last 12 months
Inside the activity.
0 purchase rows · 38 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 22 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 7 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 18, 2020 Filed Dec 22, 2020 18:55 UTC |
Donovan Michael PatrickVP Operations
|
GrantCommon Stock | 375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-012169 · edgar.xml · nonDerivative · entry 1 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,404 F1 · shares: This reflects the number of restricted stock units that became vested as of December 18, 2020. F1 · price: This reflects the number of restricted stock units that became vested as of December 18, 2020. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 17:54 UTC |
MARIANI PETER JChief Financial Officer
|
GrantCommon Stock | 1,900 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-012162 · edgar.xml · nonDerivative · entry 1 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,900 F1 · shares: This reflects the number of restricted stock units that became vested as of December 18, 2020. F1 · price: This reflects the number of restricted stock units that became vested as of December 18, 2020. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 16:38 UTC |
Friedman Mark LouisVP,Regulatory & Quality
|
GrantCommon Stock | 375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-012160 · edgar.xml · nonDerivative · entry 1 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,989 F1 · shares: This reflects the number of restricted stock units that became vested as of December 18, 2020. F1 · price: This reflects the number of restricted stock units that became vested as of December 18, 2020. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 21:41 UTC |
DeVinney Erick WayneVP, Clinical&Translational Sc
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $4.81 | $0.00 |
DisclosureSEC source: 0001179110-20-012059 · edgar.xml · derivative · entry 3 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2021-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 21:41 UTC |
DeVinney Erick WayneVP, Clinical&Translational Sc
|
Tax withholdingCommon Stock | 4,373 | $16.50 | $72,154.50 |
DisclosureSEC source: 0001179110-20-012059 · edgar.xml · nonDerivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,683 F2 · shares: Represents the number of shares swapped to cover the exercise price of the options exercised via an attestation method stock swap in accordance with Rule 16b-3. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 21:41 UTC |
DeVinney Erick WayneVP, Clinical&Translational Sc
|
Exercise / conversionCommon Stock | 15,000 | $4.81 | $72,150.00 |
DisclosureSEC source: 0001179110-20-012059 · edgar.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,056 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of shares that became vested as of January 2, 2018. Read SEC document |
| December 03, 2020 Filed Dec 7, 2020 19:39 UTC |
Friedman Mark LouisVP,Regulatory & Quality
|
Exercise / conversionEmployee Stock Options (right to buy) · Derivative | 3,187 | $3.67 Strike: $3.67 | $11,696.29 |
DisclosureSEC source: 0001179110-20-011706 · edgar.xml · derivative · entry 4 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,187 shares Expires 2021-12-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2020 Filed Dec 7, 2020 19:39 UTC |
Friedman Mark LouisVP,Regulatory & Quality
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 625 | $4.81 Strike: $4.81 | $3,006.25 |
DisclosureSEC source: 0001179110-20-011706 · edgar.xml · derivative · entry 3 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 625 shares Expires 2021-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2020 Filed Dec 7, 2020 19:39 UTC |
Friedman Mark LouisVP,Regulatory & Quality
|
Exercise / conversionCommon Stock | 3,187 | $3.67 | $11,696.29 |
DisclosureSEC source: 0001179110-20-011706 · edgar.xml · nonDerivative · entry 2 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,614 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This Form is being filed to report the cash exercise of stock options. Read SEC document |
| December 03, 2020 Filed Dec 7, 2020 19:39 UTC |
Friedman Mark LouisVP,Regulatory & Quality
|
Exercise / conversionCommon Stock | 625 | $4.81 | $3,006.25 |
DisclosureSEC source: 0001179110-20-011706 · edgar.xml · nonDerivative · entry 1 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,427 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This Form is being filed to report the cash exercise of stock options. Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 14:56 UTC |
Zaderej Karen L.Director · CEO
|
SaleCommon Stock | 14,000 | $14.53 | $203,420.00 |
DisclosureSEC source: 0001179110-20-010948 · edgar.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 644,869 F1 · kind: Effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2020. F1 · price: Effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2020. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 15:14 UTC |
Donovan Michael PatrickVP Operations
|
SaleCommon Stock | 17,617 | $15.00 | $264,255.00 |
DisclosureSEC source: 0001179110-20-011012 · edgar.xml · nonDerivative · entry 1 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,029 F1 · kind: Effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 31, 2020. F1 · price: Effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 31, 2020. Read SEC document |
| November 04, 2020 Filed Nov 5, 2020 23:19 UTC |
Gold Mark StephenDirector
|
GiftCommon Stock | 15,596 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-010849 · edgar.xml · nonDerivative · entry 1 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust-See Footnote Disclosed balance after: 296,266 F1 · shares: The shares of common stock for Dr. Gold include 159,575 shares held jointly by Dr. Gold and his wife, indirect ownership of 20,000 shares held by Dr. Gold's spouse and indirect ownership of 92,000 shares held by MJSK, Ltd., a decedent investment trust held by Dr. Gold's family. The transaction reflected on this Form 4 relates to the gift of securities by Dr. Gold to accounts held by his adult children who do not share a household with Dr. Gold. F1 · balance_after: The shares of common stock for Dr. Gold include 159,575 shares held jointly by Dr. Gold and his wife, indirect ownership of 20,000 shares held by Dr. Gold's spouse and indirect ownership of 92,000 shares held by MJSK, Ltd., a decedent investment trust held by Dr. Gold's family. The transaction reflected on this Form 4 relates to the gift of securities by Dr. Gold to accounts held by his adult children who do not share a household with Dr. Gold. F1 · ownership.direct: The shares of common stock for Dr. Gold include 159,575 shares held jointly by Dr. Gold and his wife, indirect ownership of 20,000 shares held by Dr. Gold's spouse and indirect ownership of 92,000 shares held by MJSK, Ltd., a decedent investment trust held by Dr. Gold's family. The transaction reflected on this Form 4 relates to the gift of securities by Dr. Gold to accounts held by his adult children who do not share a household with Dr. Gold. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 22:11 UTC |
MARIANI PETER JChief Financial Officer
|
Exercise / conversionEmployee Stock Options (Right to Purchase) · Derivative | 60,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001179110-20-010770 · edgar.xml · derivative · entry 6 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 60,000 shares Expires 2023-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 22:11 UTC |
MARIANI PETER JChief Financial Officer
|
SaleCommon Stock | 1,745 | $12.41 | $21,662.43 |
DisclosureSEC source: 0001179110-20-010770 · edgar.xml · nonDerivative · entry 5 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · kind: Effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2020. F1 · price: Effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.14 to $12.96, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 4 to this Form 4. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 22:11 UTC |
MARIANI PETER JChief Financial Officer
|
SaleCommon Stock | 12,854 | $12.41 | $159,518.14 |
DisclosureSEC source: 0001179110-20-010770 · edgar.xml · nonDerivative · entry 4 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,745 F1 · kind: Effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2020. F1 · price: Effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.05 to $12.96, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 3 to this Form 4. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 22:11 UTC |
MARIANI PETER JChief Financial Officer
|
SaleCommon Stock | 1,084 | $12.41 | $13,452.44 |
DisclosureSEC source: 0001179110-20-010770 · edgar.xml · nonDerivative · entry 3 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,599 F1 · kind: Effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2020. F1 · price: Effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.05 to $12.96, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 3 to this Form 4. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 22:11 UTC |
MARIANI PETER JChief Financial Officer
|
SaleCommon Stock | 60,000 | $12.41 | $744,720.00 |
DisclosureSEC source: 0001179110-20-010770 · edgar.xml · nonDerivative · entry 2 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,683 F1 · kind: Effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2020. F1 · price: Effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.06 to $12.96, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 2 to this Form 4. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 22:11 UTC |
MARIANI PETER JChief Financial Officer
|
Exercise / conversionCommon Stock | 60,000 | $5.04 | $302,400.00 |
DisclosureSEC source: 0001179110-20-010770 · edgar.xml · nonDerivative · entry 1 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2020. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 20:10 UTC |
THOMAS PAULDirector
|
GrantStock Option (right to purchase) · Derivative | 45,910 | $0.00 Strike: $11.63 | $0.00 |
DisclosureSEC source: 0001179110-20-010142 · edgar.xml · derivative · entry 1 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,910 Underlying: Common Stock · 45,910 shares Expires 2030-09-30 F1 · derivative.exercise_date: Option grant for joining the Issuer's Board of Directors. Options vest annually in equal parts over a three year period and become fully vested on September 30, 2023 Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 20:57 UTC |
Freitag Gregory GeneDirector
|
Exercise / conversionCommon Stock · Derivative | 4,046 | $0.00 Strike: $3.67 | $0.00 |
DisclosureSEC source: 0001179110-20-009860 · edgar.xml · derivative · entry 3 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,954 Underlying: Common Stock · 4,046 shares Expires 2021-12-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 20:57 UTC |
Freitag Gregory GeneDirector
|
Exercise / conversionCommon Stock · Derivative | 9,000 | $0.00 Strike: $3.67 | $0.00 |
DisclosureSEC source: 0001179110-20-009860 · edgar.xml · derivative · entry 2 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 9,000 shares Expires 2021-12-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 20:57 UTC |
Freitag Gregory GeneDirector
|
Exercise / conversionCommon Stock | 13,046 | $3.67 | $47,878.82 |
DisclosureSEC source: 0001179110-20-009860 · edgar.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This Form is being filed to report the cash exercise of stock options for a total of 13,046 shares. Read SEC document |
| September 03, 2020 Filed Sep 8, 2020 21:37 UTC |
NEELS GUIDO JDirector
|
GrantCommon Stock | 2,591 | $11.75 | $30,444.25 |
DisclosureSEC source: 0001179110-20-009636 · edgar.xml · nonDerivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,591 F1 · shares: This reflects the number of restricted stock units that became vested as of September 3, 2020. Read SEC document |
| September 03, 2020 Filed Sep 8, 2020 21:37 UTC |
Rudelius Robert JamesDirector
|
GrantCommon Stock | 2,591 | $11.75 | $30,444.25 |
DisclosureSEC source: 0001179110-20-009635 · edgar.xml · nonDerivative · entry 1 Rudelius Robert James · CIK 0001403679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,183 F1 · shares: This reflects the number of restricted stock units that became vested as of September 3, 2020. Read SEC document |
| September 03, 2020 Filed Sep 8, 2020 21:36 UTC |
Wendell Amy McBrideDirector
|
GrantCommon Stock | 2,591 | $11.75 | $30,444.25 |
DisclosureSEC source: 0001179110-20-009634 · edgar.xml · nonDerivative · entry 1 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,924 F1 · shares: This reflects the number of restricted stock units that became vested as of September 3, 2020. Read SEC document |
| September 03, 2020 Filed Sep 8, 2020 21:36 UTC |
Levine Alan MDirector
|
GrantCommon Stock | 2,591 | $11.75 | $30,444.25 |
DisclosureSEC source: 0001179110-20-009633 · edgar.xml · nonDerivative · entry 1 Levine Alan M · CIK 0001766833 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,591 F1 · shares: This reflects the number of restricted stock unit that became vested as of September 3, 2020. Read SEC document |
| September 03, 2020 Filed Sep 8, 2020 21:36 UTC |
Blackford Quentin S.Director
|
GrantCommon Stock | 2,591 | $11.75 | $30,444.25 |
DisclosureSEC source: 0001179110-20-009632 · edgar.xml · nonDerivative · entry 1 Blackford Quentin S. · CIK 0001612451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,126 F1 · shares: This reflects the number of restricted stock units that became vested as of September 3, 2020. Read SEC document |
| September 03, 2020 Filed Sep 8, 2020 15:05 UTC |
Gold Mark StephenDirector
|
GrantCommon Stock | 2,591 | $11.75 | $30,444.25 |
DisclosureSEC source: 0001179110-20-009614 · edgar.xml · nonDerivative · entry 1 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,862 F1 · shares: The shares of common stock for Dr. Gold include 175,171 shares held jointly by Dr. Gold and his wife, indirect ownership of 20,000 shares held by Dr. Gold's spouse and indirect ownership of 92,000 shares held by MJSK, Ltd., a decedent investment trust held by Dr. Gold's family. The transaction reflected on this Form 4 relates to the number of restricted stock units that became vested as of September 3, 2020. Read SEC document |
| August 12, 2020 Filed Aug 13, 2020 19:25 UTC |
Gold Mark StephenDirector
|
GiftCommon Stock | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-008985 · edgar.xml · nonDerivative · entry 1 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust-See Footnote Disclosed balance after: 309,271 F1 · balance_after: The shares of common stock for Dr. Gold include 175,171 shares held jointly by Dr. Gold and his wife, indirect ownership of 20,000 shares held by Dr. Gold's spouse and indirect ownership of 92,000 shares held by MJSK, Ltd., a decedent investment trust held by Dr. Gold's family. The transaction reflected on this Form 4 relates to the gift of securities by Dr. Gold to accounts held by his grandchildren pursuant to the Uniform Transfer to Minors Act who do not share a household with Dr. Gold. F1 · ownership.direct: The shares of common stock for Dr. Gold include 175,171 shares held jointly by Dr. Gold and his wife, indirect ownership of 20,000 shares held by Dr. Gold's spouse and indirect ownership of 92,000 shares held by MJSK, Ltd., a decedent investment trust held by Dr. Gold's family. The transaction reflected on this Form 4 relates to the gift of securities by Dr. Gold to accounts held by his grandchildren pursuant to the Uniform Transfer to Minors Act who do not share a household with Dr. Gold. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 21:46 UTC |
NEELS GUIDO JDirector
|
GrantRestricted Stock Units · Derivative | 4,115 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-006938 · edgar.xml · derivative · entry 2 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,115 Underlying: Common Stock · 4,115 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 2, 2021, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 2, 2021, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 21:46 UTC |
NEELS GUIDO JDirector
|
GrantStock Option (right to purchase) · Derivative | 16,807 | $0.00 Strike: $9.72 | $0.00 |
DisclosureSEC source: 0001179110-20-006938 · edgar.xml · derivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,807 Underlying: Common Stock · 16,807 shares Expires 2030-06-01 F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 2, 2021, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 21:02 UTC |
Wendell Amy McBrideDirector
|
GrantRestricted Stock Units · Derivative | 4,115 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-006910 · edgar.xml · derivative · entry 2 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,115 Underlying: Common Stock · 4,115 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 21:02 UTC |
Wendell Amy McBrideDirector
|
GrantStock Option (right to purchase) · Derivative | 16,807 | $0.00 Strike: $9.72 | $0.00 |
DisclosureSEC source: 0001179110-20-006910 · edgar.xml · derivative · entry 1 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,807 Underlying: Common Stock · 16,807 shares Expires 2030-06-01 F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:59 UTC |
Rudelius Robert JamesDirector
|
GrantRestricted Stock Units · Derivative | 4,115 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-006906 · edgar.xml · derivative · entry 2 Rudelius Robert James · CIK 0001403679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,115 Underlying: Common Stock · 4,115 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:59 UTC |
Rudelius Robert JamesDirector
|
GrantStock Option (right to purchase) · Derivative | 16,807 | $0.00 Strike: $9.72 | $0.00 |
DisclosureSEC source: 0001179110-20-006906 · edgar.xml · derivative · entry 1 Rudelius Robert James · CIK 0001403679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,807 Underlying: Common Stock · 16,807 shares Expires 2030-06-01 F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:49 UTC |
Blackford Quentin S.Director
|
GrantRestricted Stock Units · Derivative | 4,115 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-006903 · edgar.xml · derivative · entry 2 Blackford Quentin S. · CIK 0001612451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,115 Underlying: Common Stock · 4,115 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:49 UTC |
Blackford Quentin S.Director
|
GrantStock Option (right to purchase) · Derivative | 16,807 | $0.00 Strike: $9.72 | $0.00 |
DisclosureSEC source: 0001179110-20-006903 · edgar.xml · derivative · entry 1 Blackford Quentin S. · CIK 0001612451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,807 Underlying: Common Stock · 16,807 shares Expires 2030-06-01 F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:25 UTC |
Ottinger BradleyGeneral Counsel and CCO
|
GrantRestricted Stock Units · Derivative | 31,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-006875 · edgar.xml · derivative · entry 2 Ottinger Bradley · CIK 0001813381 · General Counsel and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,000 Underlying: Common Stock · 31,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on June 1, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on June 1, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on June 1, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on June 1, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:25 UTC |
Ottinger BradleyGeneral Counsel and CCO
|
GrantEmployee Stock Option (right to purchase) · Derivative | 67,000 | $0.00 Strike: $9.72 | $0.00 |
DisclosureSEC source: 0001179110-20-006875 · edgar.xml · derivative · entry 1 Ottinger Bradley · CIK 0001813381 · General Counsel and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Stock · 67,000 shares Expires 2030-06-01 F1 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on June 1, 2024 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on June 1, 2022 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| June 01, 2020 Filed Jun 12, 2020 20:24 UTC Amendment |
Rudelius Robert JamesDirector
|
GrantRestricted Stock Units · Derivative | 6,173 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-007285 · edgar.xml · derivative · entry 2 Rudelius Robert James · CIK 0001403679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,173 Underlying: Common Stock · 6,173 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · shares: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and One-half of the annual equity grant value is in the form of restricted stock units. F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and One-half of the annual equity grant value is in the form of restricted stock units. F3 · derivative.underlying_shares: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units. F3 · balance_after: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units. Read SEC document |
| June 01, 2020 Filed Jun 12, 2020 20:24 UTC Amendment |
Rudelius Robert JamesDirector
|
GrantStock Option (right to purchase) · Derivative | 12,605 | $0.00 Strike: $9.72 | $0.00 |
DisclosureSEC source: 0001179110-20-007285 · edgar.xml · derivative · entry 1 Rudelius Robert James · CIK 0001403679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,605 Underlying: Common Stock · 12,605 shares Expires 2030-06-01 F3 · shares: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and One-half of the annual equity grant value is in the form of restricted stock units. F3 · derivative.underlying_shares: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units. F3 · balance_after: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units. Read SEC document |
| June 01, 2020 Filed Jun 12, 2020 20:23 UTC Amendment |
NEELS GUIDO JDirector
|
GrantRestricted Stock Units · Derivative | 6,173 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-007284 · edgar.xml · derivative · entry 2 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,173 Underlying: Common Stock · 6,173 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · shares: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 2, 2021, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 2, 2021, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. F3 · derivative.underlying_shares: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units. F3 · balance_after: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units. Read SEC document |
| June 01, 2020 Filed Jun 12, 2020 20:23 UTC Amendment |
NEELS GUIDO JDirector
|
GrantStock Option (right to purchase) · Derivative | 12,605 | $0.00 Strike: $9.72 | $0.00 |
DisclosureSEC source: 0001179110-20-007284 · edgar.xml · derivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,605 Underlying: Common Stock · 12,605 shares Expires 2030-06-01 F3 · shares: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 2, 2021, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. F3 · derivative.underlying_shares: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units. F3 · balance_after: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units. Read SEC document |
| June 01, 2020 Filed Jun 12, 2020 20:22 UTC Amendment |
Wendell Amy McBrideDirector
|
GrantRestricted Stock Units · Derivative | 6,173 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-007283 · edgar.xml · derivative · entry 2 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,173 Underlying: Common Stock · 6,173 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · shares: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. F3 · derivative.underlying_shares: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units. F3 · balance_after: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units. Read SEC document |
| June 01, 2020 Filed Jun 12, 2020 20:22 UTC Amendment |
Wendell Amy McBrideDirector
|
GrantStock Option (right to purchase) · Derivative | 12,605 | $0.00 Strike: $9.72 | $0.00 |
DisclosureSEC source: 0001179110-20-007283 · edgar.xml · derivative · entry 1 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,605 Underlying: Common Stock · 12,605 shares Expires 2030-06-01 F3 · shares: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. F3 · derivative.underlying_shares: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units. F3 · balance_after: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units. Read SEC document |
| June 01, 2020 Filed Jun 12, 2020 20:21 UTC Amendment |
Levine Alan MDirector
|
GrantRestricted Stock Units · Derivative | 6,173 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-007282 · edgar.xml · derivative · entry 2 Levine Alan M · CIK 0001766833 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,173 Underlying: Common Stock · 6,173 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · shares: The original Form 4 filed on June 3, 2020, is a duplicate filing. The updated beneficial holdings are being submitted in this Form 4/A. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. F3 · derivative.underlying_shares: The original Form 4 filed on June 3, 2020, is a duplicate filing. The updated beneficial holdings are being submitted in this Form 4/A. F3 · balance_after: The original Form 4 filed on June 3, 2020, is a duplicate filing. The updated beneficial holdings are being submitted in this Form 4/A. Read SEC document |
| June 01, 2020 Filed Jun 12, 2020 20:21 UTC Amendment |
Levine Alan MDirector
|
GrantStock Option (right to purchase) · Derivative | 12,605 | $0.00 Strike: $9.72 | $0.00 |
DisclosureSEC source: 0001179110-20-007282 · edgar.xml · derivative · entry 1 Levine Alan M · CIK 0001766833 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,605 Underlying: Common Stock · 12,605 shares Expires 2030-06-01 F3 · shares: The original Form 4 filed on June 3, 2020, is a duplicate filing. The updated beneficial holdings are being submitted in this Form 4/A. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. F3 · derivative.underlying_shares: The original Form 4 filed on June 3, 2020, is a duplicate filing. The updated beneficial holdings are being submitted in this Form 4/A. F3 · balance_after: The original Form 4 filed on June 3, 2020, is a duplicate filing. The updated beneficial holdings are being submitted in this Form 4/A. Read SEC document |
| June 01, 2020 Filed Jun 12, 2020 20:21 UTC Amendment |
Blackford Quentin S.Director
|
GrantRestricted Stock Units · Derivative | 6,173 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-007281 · edgar.xml · derivative · entry 2 Blackford Quentin S. · CIK 0001612451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,173 Underlying: Common Stock · 6,173 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · shares: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. F3 · derivative.underlying_shares: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units. F3 · balance_after: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units. Read SEC document |
| June 01, 2020 Filed Jun 12, 2020 20:21 UTC Amendment |
Blackford Quentin S.Director
|
GrantStock Option (right to purchase) · Derivative | 12,605 | $0.00 Strike: $9.72 | $0.00 |
DisclosureSEC source: 0001179110-20-007281 · edgar.xml · derivative · entry 1 Blackford Quentin S. · CIK 0001612451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,605 Underlying: Common Stock · 12,605 shares Expires 2030-06-01 F3 · shares: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. F3 · derivative.underlying_shares: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units. F3 · balance_after: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.